Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. [electronic resource]
Producer: 20041210Description: 3528-34 p. digitalISSN:- 1078-0432
- Animals
- Antineoplastic Agents -- pharmacology
- Benzamides
- Brain Neoplasms -- secondary
- Carcinoma, Small Cell -- metabolism
- Cell Line, Tumor
- Humans
- Imatinib Mesylate
- Immunoblotting
- Immunoprecipitation
- Ligands
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Nude
- NIH 3T3 Cells
- Neoplasm Metastasis
- Neoplasm Transplantation
- Phosphorylation
- Piperazines -- pharmacology
- Proto-Oncogene Proteins c-kit -- metabolism
- Pyrimidines -- pharmacology
- Signal Transduction
- Stem Cell Factor -- metabolism
- Time Factors
- Tyrosine -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.